Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table. — • Source: Shutterstock

Cartesian Therapeutics is banking on both positive mid-stage data for Descartes-08 as well as a manufacturing process designed to cut down on logistical hurdles and toxicity in order to make its CAR-T therapy a player in the generalized myasthenia gravis (MG) space.

Key Takeaways

Cartesian Therapeutics announced positive Phase IIb data for Descartes-08 in generalized myasthenia gravis and is preparing to dose the first patient in its Phase III study.

The Frederick, MD-based company announced 8 April data from the Phase IIb study of Descartes-08, the BCMA-directed autologous CAR-T cell...